Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial.
about
Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancerRandomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinomaNon-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan.Targeted therapies for gastric cancer: current status.A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction.Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer.Recent developments in chemotherapy of advanced gastric cancer.Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study.Gastric and gastro-oesophageal cancer therapy.Recent developments in the systemic therapy of advanced gastroesophageal malignancies.Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction follPhase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma.A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma.Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer.Advances in the treatment of patients with gastric adenocarcinoma.A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma.A pilot study of cisplatin, irinotecan, leucovorin and 5-fluorouracil (PILF) combination chemotherapy for advanced gastric cancer.Chemotherapy for advanced gastric cancer: slow but further progress.Role of capecitabine and irinotecan combination therapy in advanced or metastatic gastric cancer.Overall survival benefits for irinotecan-containing regimens as first-line treatment for advanced gastric cancer: an updated meta-analysis of ten randomized controlled trials.Metastatic gastric cancer treatment: a little slow but worthy progress.Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer.Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study.Irinotecan combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy.
P2860
Q33366124-89627C3A-5303-41A4-BDC9-95ABCDA10971Q33380002-46CB362C-1F93-4190-8F60-278CD0A542C8Q33435898-D5955C14-A601-426F-88C5-0B6ABAF5AACBQ33594906-19C45B0B-F0ED-4A67-BF76-30A794ECCE2BQ34205672-7049C76D-B52E-45D5-B207-88B1B3439C3AQ34609932-3C9F745F-FE38-4ADF-8C15-FC5B31247C64Q35949510-F58E871C-4132-481B-ADC7-3AFFECE65D53Q36090047-8755EFCD-49C7-420F-946E-68687F829AF1Q36117215-54C54B31-DD47-4C6B-A7C1-3882F3C6DF14Q36327087-1BE393E9-080A-49AF-9866-704A9A62DEBCQ36376439-15AFEA02-BE03-46D6-A926-FBCF6E4DE934Q36516605-15F72588-E9A3-4D72-B906-262459F3257DQ36614148-1A4013BE-84B3-45B0-A4A9-7305C8DCA5C8Q36614602-ECC7F13E-DC66-483B-863F-3B828EB98D75Q36616011-3972EC63-5402-44E8-95B0-ACBD6AB91789Q36798382-C9C2B2E8-8D2D-4347-BD5E-1BFD3028EF74Q37323058-92CD0B69-11D7-4A74-9A49-508A2AC83A55Q37341735-B23C133E-B75E-4786-A962-FFF922A14153Q37446941-FFD12E02-1715-4A17-8639-6DF0E1672099Q37732285-9C4CA2A1-125F-41B3-965A-8951513CD784Q38034487-05C9D0EE-8066-40A6-A331-46FB9B69C73FQ38075499-0C8DB918-EE91-4140-BEB2-7CCE1626FC2BQ38222270-C49C7341-D082-4DA7-8BEE-8EAC36210227Q45154773-E99EF9CB-4A19-453E-9D49-AE5403FE188DQ51793463-6ACDE3C4-468F-49CD-8111-63A3DF137023
P2860
Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Irinotecan is active in chemon ...... a phase II multicentric trial.
@ast
Irinotecan is active in chemon ...... a phase II multicentric trial.
@en
type
label
Irinotecan is active in chemon ...... a phase II multicentric trial.
@ast
Irinotecan is active in chemon ...... a phase II multicentric trial.
@en
prefLabel
Irinotecan is active in chemon ...... a phase II multicentric trial.
@ast
Irinotecan is active in chemon ...... a phase II multicentric trial.
@en
P2093
P2860
P356
P1476
Irinotecan is active in chemon ...... a phase II multicentric trial.
@en
P2093
D Di Betta
P2860
P2888
P304
P356
10.1038/SJ.BJC.6601226
P407
P577
2003-09-01T00:00:00Z
P5875
P6179
1003666440